{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:46:58Z","timestamp":1793191618057,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Meiji Seika Pharma Co., Ltd."},{"name":"Japanese Government"},{"name":"Meiji Seika Pharma Co., Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.eplepsyres.2015.03.012","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T06:02:31Z","timestamp":1428559351000},"page":"90-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan"],"prefix":"10.1016","volume":"113","author":[{"given":"Yushi","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0005","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/brain\/aws151","article-title":"Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome","volume":"135","author":"Brunklaus","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0010","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO Study Group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0920-1211(02)00010-4","article-title":"Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial","volume":"49","author":"Coppola","year":"2002","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0020","series-title":"DIAVEY Postmarketing Survey in Transparency Commission","author":"DIAVEY","year":"2014"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0387-7604(88)80098-6","article-title":"Bromides were effective in intractable epilepsy with generalized tonic\u2013clonic seizures and onset in early childhood","volume":"10","author":"Ernst","year":"1988","journal-title":"Bran Dev."},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0030","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","article-title":"In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism","volume":"34","author":"Giraud","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0035","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1528-1157.1990.tb05494.x","article-title":"Epidemiology of severe myoclonic epilepsy in infancy","volume":"31","author":"Hurst","year":"1990","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0040","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1528-1167.2009.02179.x","article-title":"Stiripentol open study in Japanese patients with Dravet syndrome","volume":"50","author":"Inoue","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.eplepsyres.2014.02.008","article-title":"Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence","volume":"108","author":"Inoue","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1528-1167.2007.01423.x","article-title":"Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data","volume":"49","author":"Kassa\u00ef","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-2007-964867","article-title":"Topiramate in the treatment of highly refractory patients with Dravet syndrome","volume":"37","author":"Kr\u00f6ll-Seger","year":"2006","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0060","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/seiz.2000.0466","article-title":"Topiramate in the treatment of severe myoclonic epilepsy in infancy","volume":"9","author":"Nieto-Barrera","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0065","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1528-1157.1994.tb01780.x","article-title":"Treatment of severe myoclonic epilepsy in infants with bromides and its borderline variant","volume":"35","author":"Oguni","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0070","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1528-1167.2006.00477.x","article-title":"Prevalence of childhood epilepsy and distribution of epileptic syndromes: a population-based survey in Okayama, Japan","volume":"47","author":"Oka","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000265222.24102.db","article-title":"An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy","volume":"69","author":"Striano","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0080","first-page":"1120","article-title":"Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet's syndrome) (in French)","volume":"9","author":"Thanh","year":"2002","journal-title":"Arch. Pediatr."},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0085","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","article-title":"Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants","volume":"62","author":"Tran","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0090","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/epi.12303","article-title":"Stiripentol in Dravet syndrome: results of a retrospective U.S. study","volume":"54","author":"Wirrell","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.012_bib0095","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0387-7604(12)80147-1","article-title":"Early diagnosis of severe myoclonic epilepsy in infancy","volume":"14","author":"Yakoub","year":"1992","journal-title":"Brain Dev."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121115000674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121115000674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:32:59Z","timestamp":1760275979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121115000674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":19,"alternative-id":["S0920121115000674"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.03.012","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}